Brought to you by 
Paladin Labs buys miltefosine from AEterna Zentaris; transferred to Knight
02 Dec 2022
Executive Summary
AEterna Zentaris (treatments for endocrinology and oncology) has sold Canadian spec pharma Paladin Labs all rights related to miltefosine for $9.2mm (Cdn$9.1mm) in cash.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paladin Labs buys miltefosine from AEterna Zentaris; transferred to Knight
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice